FSD Pharma (NASDAQ: HUGE | CSE: HUGE | FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, has regained compliance with NASDAQ continued listing requirements. The company announced that it has received confirmation from the exchange that it is in compliance with the minimum bid price requirement of $1 per share; the company currently meets all other applicable criteria for continued listing. In September 2022, FSD Pharma was notified that it was not in compliance with the Listing Rules of the Nasdaq Stock Market. On Feb. 14, 2023, the company was notified that it regained compliance and the matter is deemed closed.
About FSD Pharma Inc.
FSD Pharma is a biotechnology company with three drug candidates in different stages of development. FSD BioSciences Inc., a wholly owned subsidiary, is focused on pharmaceutical research and development of its lead compound FSD201, a proprietary ultramicronized palmitoyl ethylamine (“PEA”) formulation for the treatment of inflammatory diseases. Lucid Psycheceuticals Inc., a wholly owned subsidiary, is focused on the research and development of its lead compounds: Lucid-PSYCH and Lucid-MS. Lucid-Psych is a molecular compound identified for the potential treatment of mental health disorders, and expanding this category, the company is investigating other products addressing acute medical needs due to the abuse of drugs such as alcohol. Lucid-MS is a molecular compound identified for the potential treatment of neurodegenerative disorders.